SCHEMBL2029883

SCHEMBL2029883

Cc1ccc(C=Cc2cc(C=Cc3cc(C(C)(C)C)cc(C(C)(C)C)c3)cc(C=Cc3cc(C(C)(C)C)cc(C(C)(C)C)c3)c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 3/20 0.58
PTGS2 P35354 3/20 0.58
NFE2L2 Q16236 7/20 0.51
ALOX5 P09917 1/20 0.50
TSHR P16473 1/20 0.48
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46
TUBA1A Q71U36 1/20 0.46
TUBA1C Q9BQE3 1/20 0.46
TUBB6 Q9BUF5 1/20 0.46
TUBB2B Q9BVA1 1/20 0.46
TUBB1 Q9H4B7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6573426 0.92 TP53 (0.46) PTGS1PTGS2NFE2L2ALOX5TUBB4A
SCHEMBL6573201 0.92 TP53 (0.46) PTGS1PTGS2NFE2L2ALOX5TUBB4A
SCHEMBL6573320 0.92 TP53 (0.46) PTGS1PTGS2NFE2L2ALOX5TUBB4A
SCHEMBL25911510 0.83 TSHR (0.71) PTGS1PTGS2NFE2L2ALOX5TSHR
SCHEMBL2033159 0.82 ALDH1A1 (0.42) PTGS1PTGS2NFE2L2ALOX5TSHR
SCHEMBL14363044 0.80 NFE2L2 (0.71) PTGS1PTGS2NFE2L2ALOX5TUBB4A
SCHEMBL6876801 0.80 ALDH1A1 (0.44) PTGS1PTGS2NFE2L2ALOX5TSHR
SCHEMBL7759021 0.80 ALDH1A1 (0.44) PTGS1PTGS2NFE2L2ALOX5TSHR
SCHEMBL13913121 0.79 TUBB1 (0.61) PTGS1PTGS2NFE2L2ALOX5TSHR
SCHEMBL8099032 0.79 TTR (0.48) PTGS1PTGS2NFE2L2ALOX5TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960557-B2 Asymmetric dendrimers ISIS INNOVATION LIMITED (GB) 2011-06-14 US disclosed
US-20090326238-A1 ASYMMETRIC DENDRIMERS ISIS INNOVATION LIMITED (GB) 2009-12-31 US disclosed
US-7537842-B2 Asymmetric dendrimers ISIS INNOVATION LIMITED (GB) 2009-05-26 US disclosed
EP-1373431-B1 ASYMMETRIC DENDRIMERS ISIS INNOVATION (GB) 2006-10-18 EP disclosed
US-20040110029-A1 Asymmetric dendrimers CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2004-06-10 US disclosed
EP-1373431-A1 ASYMMETRIC DENDRIMERS ISIS INNOVATION LIMITED (GB) 2004-01-02 EP disclosed
WO-2002066575-A1 ASYMMETRIC DENDRIMERS ISIS INNOVATION LIMITED (GB) 2002-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326238-A1 ASYMMETRIC DENDRIMERS DNM2, DYNLL2, DNM1 PTGS1 3556/4885PTGS2 2471/4885NFE2L2 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.